Key facts
- It has raised $9.1M; the latest was Later Stage VC ($2.9M) in Nov 2024.
- Notable investors include Innovate UK, Scottish Enterprise, British Business Investments, Department for International Development, Centre for Innovation Excellence in Livestock — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Biotangents
- ·The full record, as it builds
Funding rounds
No funding rounds for Biotangents are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biotangents
Developer a veterinary diagnostic device designed to detect a variety of infectious diseases in livestock. The company's device uses an isothermal amplification technology that offers molecular precision without technical demands and can be rapidly adapted to new targets with ease, enabling clients to reduce the impact of infectious diseases on livestock farming offering animal protein to be produced efficiently.
- Sector
- Healthcare
- HQ
- Penicuik, United Kingdom
- Founded
- 2015
- Employees
- 12
- Website
- biotangents.co.uk/
- Ownership
- Privately Held (backing)
Biotangents doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biotangents shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biotangents in its N-PORT filings yet. We sweep new filings monthly.